GPGrossPatternRESEARCH SYSTEM
SEC CHECK OPERATIONAL
GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

ANIP · Dec 31, 2023

ANI PHARMACEUTICALS INC. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]
Inspectable configuration

State dimensions

Filing0001023024-24-000026General Corporate
Debt relative to revenue5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.debt_to_revenue

58.68% · OPTIONAL · VALID

Capex intensity30thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.capex_revenue_ratio

1.82% · OPTIONAL · VALID

Operating cash generation75thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

24.44% · OPTIONAL · VALID

Revenue growth80thOwn-history percentile · N=20
Evidence method

Yoy · gp.fundamentals.revenue

53.87% · CORE · VALID

Inventory pressure5thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

22.84% · OPTIONAL · VALID

Operating margin75thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.operating_margin

9.65% · CORE · VALID

R&D intensity45thOwn-history percentile · N=20
Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

7.04% · OPTIONAL · VALID

SBC intensity25thOwn-history percentile · N=20
Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

4.24% · OPTIONAL · VALID

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History49 statesSelf-history eligible
Sep 30, 20218/8 normalizedLevel 3Dec 31, 20218/8 normalizedLevel 3Mar 31, 20228/8 normalizedLevel 3Jun 30, 20228/8 normalizedLevel 3Sep 30, 20228/8 normalizedLevel 3Dec 31, 20228/8 normalizedLevel 3Mar 31, 20238/8 normalizedLevel 3Jun 30, 20238/8 normalizedLevel 3Sep 30, 20238/8 normalizedLevel 3Dec 31, 20238/8 normalizedLevel 3Mar 31, 20248/8 normalizedLevel 3Jun 30, 20248/8 normalizedLevel 3Sep 30, 20248/8 normalizedLevel 3Dec 31, 20248/8 normalizedLevel 3Mar 31, 20258/8 normalizedLevel 3Jun 30, 20258/8 normalizedLevel 3Sep 30, 20258/8 normalizedLevel 3Dec 31, 20258/8 normalizedLevel 3Mar 31, 20268/8 normalizedLevel 3Jun 30, 20268/8 normalizedLevel 4
Period transition

What moved in the state?

Balance Sheet Leverage Decreased
Previous
216.86%
Current
58.68%
Delta
-158.18%
Capex Intensity Increased
Previous
1.32%
Current
1.82%
Delta
0.50%
Cash Generation Increased
Previous
24.40%
Current
24.44%
Delta
0.03%
Growth Decreased
Previous
57.27%
Current
53.87%
Delta
-3.41%
Inventory Pressure Decreased
Previous
80.85%
Current
22.84%
Delta
-58.01%
Profitability Decreased
Previous
13.61%
Current
9.65%
Delta
-3.97%
R And D Intensity Decreased
Previous
8.44%
Current
7.04%
Delta
-1.39%
Sbc Intensity Increased
Previous
4.13%
Current
4.24%
Delta
0.11%
Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.
Research Graph

Related governed research

Transitioned To · ANIP Fundamental State →Analogous To · ANIP state analogue 3 →Transitioned To · ANIP Fundamental State →Transitioned To · ANIP BALANCE_SHEET_LEVERAGE_DECREASED →Transitioned To · ANIP CAPEX_INTENSITY_INCREASED →Transitioned To · ANIP CASH_GENERATION_INCREASED →Transitioned To · ANIP GROWTH_DECREASED →Transitioned To · ANIP INVENTORY_PRESSURE_DECREASED →Transitioned To · ANIP PROFITABILITY_DECREASED →Transitioned To · ANIP R_AND_D_INTENSITY_DECREASED →Transitioned To · ANIP SBC_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.